Gevo, Amyris, Solazyme — When Will the Fog Lift for Investors?
by Jim Lane (BioInvest Digest) GEVO, SZYM, AMRS — (investor) take off delayed by fog. How soon will the potential of three of the hottest companies in the field be realized? What are the key milestones coming up for the industrial biotech’s Gold Dust Triplets?
…(B)ut more importantly we would like to note the considerable fog which equity analysts are wading through in valuing the companies for the long-term. Fog that we believe is starting to lift — and the timing of that lift is where we would like to direct your attention to today.
…Some of this — all analysts agree, is classic “sector compression” — where investor interest in giving lofty valuations to companies has evaporated based more on investor sentiment than a case of companies missing fundamental milestones.
But there have been slow-downs in scale-up — affecting Gevo and Amyris, and accounting generally for why these stock values have been more compressed.
When exactly will the fog lift — when will we have a materially clearer idea of the value of these companies? For early-stage companies it is much more about milestones rather than the kind of reporting on volume and price that drives quarterly reporting. READ MORE